Milk from 172 commercial cows with mild to moderate clinical mastitis was tested with five antibiotic residue detection assay systems. One hundred cows were treated with one of two intramammary &lactam antibiotics, and the remaining 72 cows were treated with intramuscular oxytocin. Milk samples were collected pretreatment, twice after therapy, and again 21 d following the initiation of treatment. Presumptive falsepositive assay results were tabulated from all pretreatment and 21-d milk samples and from samples collected following oxytocin therapy. The percentage of false-positive results was 43.6, 37.7, 81.7, 2.6, and 18.8% for the CITE@' probe @-lactam), Delvotest-I", Charm Farm@, LacTek@ @-lactam), and Bacillus stearothennophilus var. calidoluctis disk assay, respectively. In four of the assay systems, average SCC were significantly higher in samples yielding falsepositive results than in those with negative results. Specificity and sensitivity were estimated for each assay system, and, based on these estimates, positive and negative predictive value curves 
INTRODUCTION
On-farm screening tests devised for rapid detection of low concentrations of antibiotic residues in milk are included in the 10-point Milk and Dairy Beef Residue Prevention Program (2). which was developed collaboratively by the National Milk Producers Federation and the American Veterinary Medical Association and was designed to promote and to document responsible antibiotic use on the dairy farm.
D a i r y producers who ship milk contaminated
by antibiotics are mandated to implement this residue prevention program in cooperation with their herd veterinarians. In addition, proactive dairy producers voluntarily participate in the program. "he use of antibiotic residue detection test kits is specifically outlined in point 8 of the program (2), which recommends use of drug residue screening tests.
The antibiotic residue detection assay systems that are currently available use different assay formats; the most common assay system monitors inhibition of the growth of a test organism. This type of assay system cannot identify the nature of the compound responsible for the growth inhibition. Well-known assays in this category include Charm Farm@ (Charm Sciences Inc., Malden, MA), Delvotest-P@ (Gist Brocades Food Ingredients Inc., King of Prussia, PA), and the regulatory standard Bacillus stearothemphilus var.
calidolactis disk assay (BSDA). The BSDA is recognized by the US Department of Health and Human Services in its Grade A Pasteurized Milk Ordinance (23). The assay systems of some of the newer residue detection tests are based on immunobinding of unique antigenic structures in antibiotics or inherent antibiotic receptor interactions (4, 22).
Several researches (3, 6, 7, 9, 15, 17, 22) have reported that the accuracy of these tests varies when they are used to screen milk samples taken from individual cows; prevalence of false-positive results was high when these tests were used on individual milk samples. A falsepositive result occurs when milk that does not contain violative concentrations of exogenous antibiotic residues is identified by the test as positive for the presence of antibiotic residues. Tyler et al. (22) reported false-positive readings when test kits were used to test the milk of untreated cows with experimentally induced endotoxin mastitis; false-positive assay results occurred in 48,45, and 86% of samples examined with CITE@ probe @-lactam; IDEXX Corp., Portland, ME), Delvotest-P@, and Charm Farm@, respectively. Seymour et al. (20) found that 17% of the Delvotest-P@ results in their study were positive when the disk assay was negative. Macaulay and Packard (15) also found 11% false-positive results when the Delvotest-P@ was used on negative control samples (milk containing no exogenous antibiotics). Cullor et al. (6, 7) reported a high prevalence of false-positive results with Charm Farm@, Delvotest-P@, and CITE@ probe @-lactam).
False-positive results can arise because of the presence of an endogenous antigen similar to the test antigen, laboratory error, or failure to optimize the assay for the appropriate environment or circumstances of use. False positive assay results could be caused by the natural inhibitory substances present in milk. Kosikowski (14) discussed the significance of the natural inhibitory behavior in milk on antibiotic disk assay testing in 1963. Carlsson and Bjorck (3) found that a positive reaction with the Delvotest-P@ correlated well with increased concentrations of lactoferrin and lysozyme in milk. Concentrations of these subJournal of Dairy Science Vol. 76, No. 10. 1993 stances, which are natural antibiotics in milk, increase during normal host defense. Okada (17), using a paper disk assay, found a 10.2% false-positive rate in milk samples collected from unmedicated cows; this rate was even higher (19.7%) for milk samples in which the SCC was >300,000/ml. Okada (17) concluded that lactoferrin contributed to the growth inhibition ring that was detected with the paper disk assay.
Antibiotic residue detection assay systems have been optimized to perform under laboratory conditions in which milk from healthy cows is fortified with known concentrations of antibiotic parent compound (1, 13, 20) . This laboratory optimization protocol poses a problem when these assays are applied to field applications because milk from healthy cows is only a subset of the milk samples that are typically assayed on a commercial dairy. The components in milk from a healthy cow that has been fortified (augmented) with a parent compound of an antibiotic would be expected to differ from those in the milk of a cow that had been administered the same antibiotic and that was recovering from a systemic disease. Milk samples exhibit considerable compositional diversity, especially variation in bacteriological contamination, SCC, and content of natural antimicrobial substances. A cow can produce saleable milk that contains specific and nonspecific antibacterial factors derived from the circulatory system (16). These host defense mechanisms could cause some assays to indicate the presence of antibiotics. Residue assay systems recommended for field use should be able to produce accurate results on milk with the compositional diversity that would be expected from cows in various health and disease states.
The objective of this study was to evaluate the perfomance of five milk antibiotic residue assay&ITE@ robe @-lactam), DelvotestSunnyvale, CA), and the BSDA-n milk samples collected from 172 cows with clinical mastitis in two commercial dairy herds. Mastitis is the most common disease in California dairy cows and accounts for 38% of all reported morbidity (10). Mastitis is an inflammation of the mammary gland that increases the vascular permeability within the gland. Tests should account for mammary gland in-P@, Charm Farm B , LacTek@ @-lactam; Idetek, flammation and for the high concentrations of naturally occurring inhibitory substances derived from the circulatory system that will be present in many of the milk samples tested (4). Test kits must be able to differentiate between a milk sample from an untreated cow recovering from mastitis and the milk of a cow treated with antibiotics. Cows experiencing naturally occurring mastitis form a logical study population to determine the accuracy of the residue detection assay systems in the field.
MATERIALS AND METHODS

Study Population and Trial Lksign
This trial involved cows in two northern California commercial dairy herds. In these drylot dauy operations, cows were milked twice daily and were managed in a way that is typical of established California commercial herds. Both dairies had a hospital string that housed all cows receiving medications. Written hospital records were maintained detailing the dose, route of administration, and recipient of all medications used on the dairy. Cows in first or subsequent lactations were enrolled on this trial immediately upon developing a case of mild to moderate clinical mastitis as determined by the appearance of abnormal milk, swelling of a quarter, or both. Cows that exhibited systemic signs of illness resulting from mastitis, such as fever or diarrhea, were excluded from the trial to minimize withdrawal of cows from the trial because of the administration of additional therapies.
These 172 cows were part of a larger clinical trial investigating the efficacy of certain mastitis treatment programs (11). Cows with clinical mastitis were randomly assigned to one of three different mastitis therapies. Fifty cows (25 cows per herd) were treated with Amoxi-Mast@ (Smith Kline Beecham, Exton, PA) intramammary tubes according to the label directions. Amoxi-Mast@ intramanunary tubes contain 62.5 mg of amoxicillin trihydrate per disposable syringe, and the milk withdrawal period following the last intramammary treatment is 60 h. One intramammary tube was administered to the infected quarter after each of the first three milkings following the onset of mastitis. Twenty-five cows from each herd were treated with Cefa-Lak@ (Aveco, Ft. Dodge, IA) intramammary tubes following milking according to the label directions. Cefa-LAC@ intramammary tubes contain 200 mg of cephapirin sodium activity and have a 96-h withdrawal time following the final intramammary treatment. One intramammary tube was administered to the affected quarter immediately after the first two milkings following enrollment. The remaining 72 cows (36 cows from each dairy) did not receive antibiotic therapy for the treatment of mastitis but instead received 100 IU of oxytocin (Anthony products Co., Arcadia, CA) intramuscularly immediately prior to each of the first three milkings following enrollment.
To facilitate adherence to the trial protocol, only one antibiotic therapy was in use at one time on the dairy. In each herd, a group of cows was treated with oxytocin contemporaneously with each antibiotic group. The first 43 mastitic cows were randomly assigned either to the amoxicillin group (n = 25) or to the oxytocin group (n = 18). The next 43 mastitic cows were randomly assigned either to the cephapirin group (n = 25) or to the oxytocin group (n = 18). All mastitic cows were housed in the hospital string for the milk withdrawal period specified for the intramammary tubes. The cows treated with oxytocin (nonantibiotic rherapy) were kept in the hospital string for the same number of milkings as the concurrent antibiotic therapy group to facilitate sample collection. If an infected quarter did not make satisfactory progress to recovery during the observation period or worsened, the cow was treated by dairy personnel according to the usual protocols, and the data for those cows were omitted from the final analysis.
Milk Sampling
Foremilk samples were aseptically collected, immediately refrigerated at 4'C, and transported on ice twice weekly to the laboratory where they were processed within 2 h of arrival. Eight milk samples were collected from each cow enrolled in the trial. Samples were collected from the affected quarter and from the three remaining normal quarters (composite sample) immediately upon enrollment of the cow in the trial. Samples from milking 1 were, therefore, pretreatment samples and preceded the first milking at which mastitis therapies were administered.
The second set of samples was collected preceding milking 4 and consisted of a sample from the affected quarter and a composite sample from the other three normal quarters. A third set of samples was collected either at milking 9 for the amoxicillin group and the concurrent oxytocin group or at milking 11 for the cephapirin group and its concurrent oxytocin group. A final set of samples was collected 21 d after initial enrollment on the trial. The milk from the majority of the trial cows at this final sampling appeared to be normal and entered the farm bulk tank and the milk supply. A 21-d composite sample was not collected from the first 48 mastitic cows enrolled in the trial because this procedure was not initially included in the trial protocol.
Antibiotic Residue Screening Aswys
Milk samples were analyzed qualitatively for &lactam antibiotic residues using five assay systems designed to detect the presence of antibiotic residues in milk. These assays were CITE" probe @-lactam), Delvotest-P, charm Farm@, LacTek@ @-lactam), and BSDA. Tests other than BSDA were performed at the University of California Davis Food Safety Laboratory. Assays were performed according to the manufacturers' directions by a number of laboratory technicians. Daily accuracy of all tests was monitored by performance on p itive and negative control milk samples. The laboratory assay negative control was prepared fresh daily from antibiotic-free UHT milk purchased from a commercial retailer. The p itive control laboratory sample was made from the UHT milk sample fortified with 100 ng/ml of sodium ampicillin (Wyeth Laboratories, Philadelphia, PA) and 400 ng/ml of sodium cephapirin (Ft. Dodge Laboratories Inc., Ft. Dodge, IA). This mixture resulted in a final concentration of 500 ng/ml of &lactam antibiotics in the positive control sample. The BSDA was performed at the California Department of Food and Agriculture Milk Laboratory, a certified milk regulatory laboratory. Technicians had no knowledge of the residue status of the milk samples that they analyzed.
Other Analyses All milk samples were cultured, and colonies were identified by standard milk microbial Journal of Dairy Science Vol. 76, No. 10, 1993 methods (21). In addition, SCC were determined using a Fossomatic 360 cell counter (Fossomatic, Eden Prairie, MN) on milk samples collected on the final 42 cows enrolled on farm 1, and all of the cows enrolled on farm 2. The SCC were not determined for the first 44 mastitic cows enrolled in the trial on farm 1, as they were the earliest enrollments, and SCC analysis was not initially included in the trial protocol.
Statistical Analysis
Prior to data analysis, the treatment history of every cow in the trial was examined. Records for any cow with recent antibiotic therapy prior to its enrollment in the trial, a short dry period following dry cow therapy, or additional therapy during the trial period were removed from the original data set. If a cow was sold prior to the 21-d sampling, the earlier samples remained in the data set, and the 2 1 d samples were treated as missing data. For each assay, specificity and sensitivity point estimates were calculated using standard methods. Based on these sensitivity and specificity point estimates, positive and negative predictive value curves were graphed for each assay system as the prevalence of milk samples containing detectable concentrations of exogenous antibiotic residues in the population was varied from 0 to 100%. Mean SCC for positive and negative assay results were compared by t tests or Mann-Whitney Wilcoxon U tests and considered to be significant at P < .05. The nonparametric procedun was used when the sample sizes were small and when data were not normal. All data were analyzed using StatistixB version 4.0 (Analytical Software, St. Paul, MN). Table 1 lists the bacteria that were identified from the quarter sample collected at milking 1. Colifom and environmental streptococci were the most commonly isolated pathogens.
RESULTS
The other category included 11 coagulasenegative staphylococci, two Corynebacterium species, one Bacillus cereus, and six samples from which more than one organism was identified. Table 2 shows the percentage of positive results recorded for each of the three therapy groups. Fewer samples were available for analysis after milking 1 because cows were withdrawn from the trial by the d a q owners. Only 84 mastitic cows were evaluated using Charm Farm@ because of a corporate recall of the loaned equipment. Samples from milking 1 (pretreatment), 21-d samples, and oxytocin therapy group samples were expected to be free of exogenous antibiotic residues. Positive samples in this group were considered to be false positives. The cumulative percentage of false-positive results was 43.6 (n = 8391, 37.7 (n = 839), 81.7 (n = 387), 2.6 (n = 836), and 18.8% (n = 819) for the CITE" probe @-lactam), Delvotest-P@, Charm Farm", LacTek@ @-lactam), and BSDA, respectively. Table 3 gives estimates of the specificity, percentage detected, and sensitivity based on the quarter sample data at milking 4. Sensitivity refers to the probability of correct identification of positive (antibiotic-treated) cows. Sensitivity values were combined for the two antibiotic groups and based on the assumption that the quarter samples at milking 4 from cows in the two antibiotic therapy groups had detectable antibiotic residues. The detection estimate considers only the subset of cows that tested negative at milking 1 and then tested positive at milking 4 after antibiotic therapy. If an assay had a very low specificity (i.e., many of the samples from milking 1 were false positive), this detection value was based on a small sample size.
Sensitivity values can only be determined from the quarter samples of the antibiotic therapy groups at milking 4, because these were the only quarter samples expected to contain detectable antibiotics. However, specificity values can be calculated on the basis of a number of samplings. Specificity refers to the probability of correct identification of truenegative (untreated) cows. Values for samples at milking 1 (all therapy groups), milkings 4,9, and 11 samples (oxytocin group), and at 21 d (all therapy groups) were used to calculate specificity range because no samples in these groups were expected to contain detectable antibiotic residues. Table 3 includes the range of specificity estimates calculated from either quarter or composite samples at the four different sampling periods, and the specificity point estimate based on quarter samples taken from the oxytocin therapy group at milking 4.
Predictive Value of Antibiotic Residue Assay Systems
Positive predictive value is the probability that a sample that tests positive does contain violative concentrations of exogenous antibiotic residues, and the negative predictive value is the probability that a sample that tests negative does not contain such residues. If a dairy operation used no antibiotics, the positive predictive value of any assay system would be 0. If 100% of the cows in a herd were treated and all of the milk contained antibiotic residues, the positive predictive value of any assay system would be 1.
Figures 1 to 5 depict the positive and negative predictive value curves for each of the five assay systems based on the sensitivity and specificity point estimates listed in Table 3 . Predictive values alter as the prevalence of milk samples containing detectable concentrations of antibiotic residues in the population ranges from 0 to 100%. The negative predictive value curve in Figure 3 is the horizontal line with a value of 1. A negative predictive value of 1 indicates that the test never gave a negative result on milk from a treated cow.
This test would be ideal if it also never gave a positive result on milk from an untreated cow.
As the prevalence of antibiotic residues in milk decreases, all tests must have a high specificity to minimize the number of falsepositive samples. At 0% prevalence of antibiotics in the population, a negative assay would Sensitivity estimates are based on the percentage of positive assays that were read from each assay kit when used on quarter samples collected from antibiotic therapy groups at milking 4. Detection estimates are based on the percentage of positive assays that were read from each assay kit when used on quarter samples collected from antibiotic therapy groups at milking 4 of the subset of cases that were negative at milking 1. Specificity point estimates are based on the percentage of negative assays that were read from each assay kit when used on quarter samples collected from the oxytocin therapy group only at milking 4.
Zspecificity ranges include specificity point estimates calculated from the four sampling times using either quarter or composite samples that were expected to be free of residues. Samples were included from milking 1 and 21 d from all therapy groups, and from milkings 4, 9, and 11 from the oxytocin therapy group. 31DEXX Corp., Portland, ME. residues. It is equally important that the negative predictive value remain high as the population antibiotic prevalence increases from 0% to ensure residue-free milk for the consumer. The assay must accurately detect only negative samples to protect against false-negative results. Figure 4 shows positive and negative predictive value curves that most closely approximate the ideal for an individual assay system. Table 4 lists the average SCC tabulated for both the positive and negative assay results obtained from samples taken at the four sampling periods. Only samples that were expected to be residue-free were included in these SCC calculations, i.e., all samples from milking 1 (pretreatment), 21-d samples, and oxytocin therapy group samples from milkings 4,9, and 11. The SCC was determined on all milk samples collected from cows enrolled at the second trial site and on the cows enrolled in the latter half of the trial at the first trial site (cephapirin therapy group and the concurrent oxytocin therapy group), but not on samples collected from cows enrolled on the trial earlier at dauy 1 because the determination of SCC was not initially included in the trial protocol. Unfortunately, the Charm Farm* equipment was not available throughout the entire trial, so little data exist on the relationship of SCC to the outcome of this residue assay system. All of the positive results shown in Table 4 Bacillus srearothermophilus vu.
SCC and False-Posltlve Tests
trial, and these were the samples on which SCC were performed.
with a lower SCC in milking 1 composite samples using the LacTeks test without apparent explanation. As the cow recovered from mastitis, the SCC of the affected quarter decreased, and a significantly higher average SCC was often associated with positive assay outcomes. The fact that specificity point estimates altered during the course of mastitis and that SCC was associated with false-positive outcomes makes questionable which milk component is being detected by some of the residue assay systems. 15, 18) . Any bacterial growth inhibitor that is present in milk causes a positive result in systems that monitor whether the sample under investigation inhibits the growth of a test organism. Charm Farm@ had very low specificity (9.1%) when it was used to screen quarter samples at milking 4 from cows that did not receive antibiotic therapy. This level of specificity is too low for a producer using a screening test to determine whether the milk from an individual cow can enter the bulk tank.
The CITE@ probe @-Lactam) assay, which uses a binding protein on a membrane matrix to bind the P-lactam antibiotic (blot ELISA), also had low specificity (30.4%). Cullor et al. (7) found that small amounts of serum or plasma proteins contributed to false-positive results in this assay system; possibly, nonspecific binding of naturally occumng substances in bovine milk resulted in the false positives evident in this investigation. Of the antibiotic residue assays examined, only the LacTek@ @-lactam) assay appeared to have satisfactory specificity (92.896) and sensitivity (98.6%). This test, which is based on the immunobinding principles of the ELISA system, uses a P-lactam specific antibody. The LacTek@ @-lactam) assay system requires the use of a spectrophotometer and may be more appropriate as a laboratory test. Samples can be processed at the laboratory in a relatively short time (20 min) with this assay system. Two misclassification errors (false positives and false negatives) can occur with these antibiotic screening tests. The first error is of concern to the dairy producer who does not want to discard milk unnecessarily, and the second error is of concern to the consumer who wants assurance that the milk supply is free of antibiotics. The ideal test would have specificity and sensitivity values approaching 1 and, hence, high positive and negative predictive values over the range of residue prevalence (0 to 30%) likely to be encountered on dairies. If a test with a specificity of 10% and a sensitivity of 100% is applied to a population of 100 cows with 1 treated cow, that cow would be identified with certainty, but 89.1 cows (.9 x 99) also would be incorrectly identified as positive, Le., false-positive results.
Such a test would ensure that the milk was residue-free but would have a negative economic effect on the dairy producer who would be required to ensure that milk from 89 residue-free cows did not enter the bulk tank. When the prevalence of residues is likely to be low, specificity becomes critically important to prevent discard of saleable milk and excessive financial loss to the dary producer. This falsepositive outcome also creates distrust in the consumer or regulatory system by inaccurately indicating that the producer is not following regulatory guidelines.
We also detected probable false-negative assay outcomes from the quarter samples collected at milking 4 in the antibiotic therapy groups. Four of the five assay systems in this study failed to detect residues in some of the quarter samples at milking 4 from treated cows and, hence, had sensitivities ~1 0 0 % . These quarter samples at milking 4 cannot be unequivocally considered to contain residues; the gland may have cleared all of the antibiotic administered before milking 4. If this clearance occurred, assay sensitivities ~1 0 0 % are underestimated in Table 3 . False-negative assays are of product safety concern because milk with residues could test negative and thus enter the bulk tank and possibly the milk supply. False-negatives could also result in a significant fiscal penalty to the dairy producer if that milk were to test positive at the creamery. Using the same example, if a test with a specificity of 100% and a sensitivity of 10% is applied to a population of 100 cows with 1 treated cow, all of the untreated cows would test negative, but the probability that the milk from the treated cow would be identified as positive would be 1 x .1 = .l.
The results of this study indicate that some of the antibiotic residue screening assays are not currently specific enough for producers to use on individual cow milk samples in the field. The milk samples studied were typical of those that would be tested by a commercial dauy producer. Producers would normally test milk from a treated cow at the end of the withholding period to confirm that her milk was free of residues and could be returned to the bulk tank. Table 2 shows that in this trial many samples from the antibiotic therapy groups were assay positive at the end of the published milk withholding time. The producer would not be able to know whether these results were positive because of extended retention of the intramammary antibiotics in the mammary gland or whether they were false-positive results. A producer cannot confirm the real antibiotic residue status of a sample that results in a positive assay outcome.
The specificity and sensitivity values discussed herein refer only to the epidemiologic definitions, which differ from the subset of analytical definitions in which sensitivity refers to the minimum concentration of a compound that a particular assay system can detect and specificity refers to the type of compounds that can be detected. Although it is important to optimize the analytical abilities of a test kit, the epidemiologic specificity and sensitivity of the assay system are equally important to optimize. Such optimization must be performed under field conditions to ensure reliable and accurate results when the assay is used for commercial applications. These findings should not be construed as a criticism of 10-point Milk and Dairy Beef Residue Prevention Program. Until more accurate residue testing kits for individual cows become available, the 9 remaining control points become increasingly important to ensure that milk containing antibiotic residues does not enter the milk supComprehensive monitoring and residue screening programs indicate a low prevalence of antibiotic residues in bulk tank milk (12) . Populations with a low prevalence of antibiotic use tend to produce a high proportion of falsepositive results even when screened with assays of moderate to high (60 to 90%) specificity. This investigation did not examine the bulk tank performance of the residue assays. Preliminary findings (6) support the need to assess the accuracy of residue assay systems used to test bulk tank milk. The natural inhibitory substances in the milk of an individual cow, which likely caused the high percentage of false-positive results in this study, would be diluted in bulk tank milk. The degree of dilution would depend on the size and health status of the herd. Small herds with a number of freshened or subclinical cows would be particularly prone to errors in a bulk tank residue detection system with low specificity. Because dairy producers receive substantial fiscal and Ply.
regulatory penalties for shipping milk with antibiotic residues, accuracy, epidemiological specificity, and sensitivity must be established for the assays that are used to examine bulk tank milk. As the prevalence of antibiotic residues decreases in the future, use of a test or a combination of tests with both high sensitivity and high specificity will become increasingly necessary.
CONCLUSIONS
The need for field testing of an antibiotic residue test kit for on-farm cowside use has been demonstrated in this investigation. Cowside tests must have both high specificity and sensitivity to be of value to the dairy producer and regulatory authorities. This study on milk from mastitic cows showed that the Charm Farm@, Delvotest-P@, and ClTE? probe @-lactam) cowside tests had low to very low specificities. False-positive results in these assay systems were often associated with elevated SCC. The field performance and accuracy of these tests on individual cow milk samples need to be optimized before they can be recommended as cowside tests for commercial dairies.
